Hikma Pharmaceuticals Plc's (HIK) Neutral Rating Reaffirmed at JP Morgan Chase & Co

Xavier Trudeau
Juin 26, 2017

Jefferies Group LLC's target price would suggest a potential downside of 10.38% from the company's previous close. Finally, Jefferies Group LLC cut shares of Hikma Pharmaceuticals Plc to an "underperform" rating and reduced their price target for the company from GBX 2,162 ($27.35) to GBX 1,450 ($18.34) in a research report on Wednesday, May 17th.

Hikma Pharmaceuticals Plc (LON:HIK)'s stock had its "neutral" rating reaffirmed by research analysts at J P Morgan Chase & Co in a research note issued to investors on Monday, May 22nd, MarketBeat.com reports. Peel Hunt maintained the stock with "Buy" rating in Friday, February 24 report. J P Morgan Chase & Co downgraded shares of Hikma Pharmaceuticals Plc to a "neutral" rating and lifted their target price for the company from GBX 2,100 ($26.76) to GBX 2,400 ($30.58) in a report on Thursday, March 16th. HSBC Holdings plc restated a "reduce" rating and issued a GBX 1,800 ($22.77) target price on shares of Hikma Pharmaceuticals Plc in a report on Friday, May 5th. The firm earned "Buy" rating on Wednesday, September 2 by Shore Capital. Jefferies maintained Hikma Pharmaceuticals Plc (LON:HIK) on Monday, November 2 with "Buy" rating. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company's stock. The stock of Hikma Pharmaceuticals Plc (LON:HIK) earned "Overweight" rating by JP Morgan on Tuesday, August 25.

JP Morgan maintained Hikma Pharmaceuticals Plc (LON:HIK) on Thursday, August 20 with "Overweight" rating. The company's 50-day moving average price is $23.56 and its 200 day moving average price is $23.98. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,573.00 and a 12 month high of GBX 2,703.00. The firm has a market cap of $5.13 billion and a P/E ratio of 32.19. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & global copyright law. Fool.Co.Uk's article titled: "Why I'd buy and hold Hikma Pharmaceuticals plc for the next decade" and published on March 15, 2017 is yet another important article. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/06/23/hikma-pharmaceuticals-plc-hik-given-underperform-rating-at-jefferies-group-llc-updated-updated.html. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL